Janux Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $591.00K, a 24.13% decline year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $443.00K, a 38.87% increase year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $779.00K, a 64.69% increase year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.22M, a 54.29% increase from fiscal 2024.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $792.00K, a 2.59% increase from fiscal 2023.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $772.00K, a 54.71% increase from fiscal 2022.
- Janux Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $499.00K, a 204.27% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $591.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $443.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | $779.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $319.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $792.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $473.00K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $772.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2023-06-30 | $528.00K 10-Q · filed 2024-08-07 | |
| 2022-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $499.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $307.00K 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $164.00K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |